ErbB receptors and their growth factor ligands in pediatric intestinal inflammation

Pediatric Research

Volumn 75, Issue 1-2, 2014, Pages 127-132

  Frey, Mark R ^a,b   Brent Polk, D ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; PROBIOTIC AGENT;

CHILDHOOD DISEASE; COLITIS; DRUG TARGETING; ENTERITIS; HUMAN; INFLAMMATORY BOWEL DISEASE; MOLECULAR PATHOLOGY; NECROTIZING ENTEROCOLITIS; NONHUMAN; PARENTERAL NUTRITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; WOUND HEALING; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); INTESTINE EPITHELIUM CELL; PATHOGENESIS; REDUCTION; TOTAL PARENTERAL NUTRITION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; CROHN DISEASE; DISEASE MODELS, ANIMAL; DRUG DESIGN; ENTEROCOLITIS, NECROTIZING; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; LIGANDS; MOLECULAR TARGETED THERAPY; PARENTERAL NUTRITION, TOTAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 84900400868     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2013.210     Document Type: Review

References (80)

1. Martin-de-Carpi J, Rodriguez A, Ramos E, Jimenez S, Martinez-Gomez MJ, Medina E. Increasing incidence of pediatric inflammatory bowel disease in Spain (1996-2009): the SPIRIT registry. Inflamm Bowel Dis 2013;19:73-80.
2. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci 2013;58:519-25.
3. Hunter CJ, Upperman JS, Ford HR, Camerini V. Understanding the susceptibility of the premature infant to necrotizing enterocolitis (NEC). Pediatr Res 2008;63:117-23.
4. Blakely ML, Lally KP, McDonald S, et al.; NEC Subcommittee of the NICHD Neonatal Research Network. Postoperative outcomes of extremely low birth-weight infants with necrotizing enterocolitis or isolated intestinal perforation: a prospective cohort study by the NICHD Neonatal Research Network. Ann Surg 2005;241:984-9; discussion 989-94.
5. Kudsk KA, Croce MA, Fabian TC, et al. Enteral versus parenteral feeding. Effects on septic morbidity after blunt and penetrating abdominal trauma. Ann Surg 1992;215:503-11; discussion 511-3.
6. Feng Y, Teitelbaum DH. Epidermal growth factor/TNF-a transactivation modulates epithelial cell proliferation and apoptosis in a mouse model of parenteral nutrition. Am J Physiol Gastrointest Liver Physiol 2012;302:G236-49.
7. Ezri J, Marques-Vidal P, Nydegger A. Impact of disease and treatments on growth and puberty of pediatric patients with inflammatory bowel disease. Digestion 2012;85:308-19.
8. Cucchiara S, Escher JC, Hildebrand H, Amil-Dias J, Stronati L, Ruemmele FM. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 2009;48:257-67.
9. Bjkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Fkkilä M. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 2013;48:543-51.
10. Baert F, Moortgat L, Van Assche G, et al.; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463-8; quiz e10-1.
11. Feng J, Besner GE. Heparin-binding epidermal growth factor-like growth factor promotes enterocyte migration and proliferation in neonatal rats with necrotizing enterocolitis. J Pediatr Surg 2007;42:214-20.
12. Frey MR, Dise RS, Edelblum KL, Polk DB. p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration. EMBO J 2006;25:5683-92.
13. Yamaoka T, Yan F, Cao H, et al. Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis. Proc Natl Acad Sci USA 2008;105:11772-7.
14. Frey MR, Hilliard VC, Mullane MT, Polk DB. ErbB4 promotes cyclooxygenase-2 expression and cell survival in colon epithelial cells. Lab Invest 2010;90:1415-24.
15. Polk DB. Epidermal growth factor receptor-stimulated intestinal epithelial cell migration requires phospholipase C activity. Gastroenterology 1998;114:493-502.
16. Yamaoka T, Frey MR, Dise RS, Bernard JK, Polk DB. Specific epidermal growth factor receptor autophosphorylation sites promote mouse colon epithelial cell chemotaxis and restitution. Am J Physiol Gastrointest Liver Physiol 2011;301:G368-76.
17. Bernard JK, McCann SP, Bhardwaj V, Washington MK, Frey MR. Neuregulin-4 is a survival factor for colon epithelial cells both in culture and in vivo. J Biol Chem 2012;287:39850-8.
18. Good M, Siggers RH, Sodhi CP, et al. Amniotic fluid inhibits Toll-like receptor 4 signaling in the fetal and neonatal intestinal epithelium. Proc Natl Acad Sci USA 2012;109:11330-5.
19. Alexander RJ, Panja A, Kaplan-Liss E, Mayer L, Raicht RF. Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in inflammatory bowel disease. Dig Dis Sci 1995;40:485-94.
20. Oikonomou KA, Kapsoritakis AN, Kapsoritaki AI, et al. Downregulation of serum epidermal growth factor in patients with inflammatory bowel disease. Is there a link with mucosal damage Growth Factors 2010;28:461-6.
21. Brennan PJ, Kumagai T, Berezov A, Murali R, Greene MI. HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene 2002;21:328.
22. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 2010;107:7692-7.
23. Kaushansky A, Gordus A, Budnik BA, Lane WS, Rush J, MacBeath G. System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties. Chem Biol 2008;15:808-17.
24. Finney KJ, Ince P, Appleton DR, Sunter JP, Watson AJ. A trophic effect of epidermal growth factor (EGF) on rat colonic mucosa in organ culture. Cell Tissue Kinet 1987;20:43-56.
25. Harari D, Tzahar E, Romano J, et al. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 1999;18:2681-9.
26. Skov Olsen P, Poulsen SS, Therkelsen K, NexE. Oral administration of synthetic human urogastrone promotes healing of chronic duodenal ulcers in rats. Gastroenterology 1986;90:911-7.
27. Egger B, Bhler MW, Lakshmanan J, Moore P, Eysselein VE. Mice harboring a defective epidermal growth factor receptor (waved-2) have an increased susceptibility to acute dextran sulfate-induced colitis. Scand J Gastroenterol 2000;35:1181-7.
28. DubPE, Yan F, Punit S, et al. Epidermal growth factor receptor inhibits colitis-associated cancer in mice. J Clin Invest 2012;122:2780-92.
29. Egger B, Procaccino F, Lakshmanan J, et al. Mice lacking transforming growth factor alpha have an increased susceptibility to dextran sulfateinduced colitis. Gastroenterology 1997;113:825-32.
30. Egger B, Carey HV, Procaccino F, et al. Reduced susceptibility of mice overexpressing transforming growth factor alpha to dextran sodium sulphate induced colitis. Gut 1998;43:64-70.
31. Procaccino F, Reinshagen M, Hoffmann P, et al. Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology 1994;107:12-7.
32. Yan F, Cao H, Cover TL, et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest 2011;121:2242-53.
33. Yan F, Polk DB. Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases. Gut Microbes 2012;3:25-8.
34. McCole DF, Truong A, Bunz M, Barrett KE. Consequences of direct versus indirect activation of epidermal growth factor receptor in intestinal epithelial cells are dictated by protein-tyrosine phosphatase 1B. J Biol Chem 2007;282:13303-15.
35. Brandl K, Sun L, Neppl C, et al. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc Natl Acad Sci USA 2010;107:19967-72.
36. McCole DF, Rogler G, Varki N, Barrett KE. Epidermal growth factor partially restores colonic ion transport responses in mouse models of chronic colitis. Gastroenterology 2005;129:591-608.
37. Zaiss DM, van Loosdregt J, Gorlani A, et al. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity 2013;38:275-84.
38. Zhang Y, DubPE, Washington MK, Yan F, Polk DB. ErbB2 and ErbB3 regulate recovery from dextran sulfate sodium-induced colitis by promoting mouse colon epithelial cell survival. Lab Invest 2012;92:437-50.
39. Hormi K, Cadiot G, Kermorgant S, et al. Transforming growth factoralpha and epidermal growth factor receptor in colonic mucosa in active and inactive inflammatory bowel disease. Growth Factors 2000;18:79-91.
40. Nishimura T, Andoh A, Inatomi O, et al. Amphiregulin and epiregulin expression in neoplastic and inflammatory lesions in the colon. Oncol Rep 2008;19:105-10.
41. Hoffmann P, Reinshagen M, Zeeh JM, et al. Increased expression of epidermal growth factor-receptor in an experimental model of colitis in rats. Scand J Gastroenterol 2000;35:1174-80.
42. Hoffmann P, Zeeh JM, Lakshmanan J, et al. Increased expression of transforming growth factor alpha precursors in acute experimental colitis in rats. Gut 1997;41:195-202.
43. Frey MR, Edelblum KL, Mullane MT, Liang D, Polk DB. The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF. Gastroenterology 2009;136:217-26.
44. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003;349: 350-7.
45. Warner BW, Warner BB. Role of epidermal growth factor in the pathogenesis of neonatal necrotizing enterocolitis. Semin Pediatr Surg 2005;14: 175-80.
46. Shin CE, Kim SS, Chwals WJ. Salivary gland choristoma of the anterior chest wall. J Pediatr Surg 2000;35:1506-7.
47. Dvorak B, Khailova L, Clark JA, et al. Comparison of epidermal growth factor and heparin-binding epidermal growth factor-like growth factor for prevention of experimental necrotizing enterocolitis. J Pediatr Gastroenterol Nutr 2008;47:11-8.
48. Radulescu A, Zorko NA, Yu X, Besner GE. Preclinical neonatal rat studies of heparin-binding EGF-like growth factor in protection of the intestines from necrotizing enterocolitis. Pediatr Res 2009;65:437-42.
49. Dvorak B, Halpern MD, Holubec H, et al. Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model. Am J Physiol Gastrointest Liver Physiol 2002;282:G156-64.
50. Clark JA, Lane RH, Maclennan NK, et al. Epidermal growth factor reduces intestinal apoptosis in an experimental model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 2005;288:G755-62.
51. Halpern MD, Holubec H, Saunders TA, et al. Bile acids induce ileal damage during experimental necrotizing enterocolitis. Gastroenterology 2006;130:359-72.
52. Clark JA, Doelle SM, Halpern MD, et al. Intestinal barrier failure during experimental necrotizing enterocolitis: protective effect of EGF treatment. Am J Physiol Gastrointest Liver Physiol 2006;291:G938-49.
53. Halpern MD, Dominguez JA, Dvorakova K, et al. Ileal cytokine dysregulation in experimental necrotizing enterocolitis is reduced by epidermal growth factor. J Pediatr Gastroenterol Nutr 2003;36:126-33.
54. Sullivan PB, Lewindon PJ, Cheng C, et al. Intestinal mucosa remodeling by recombinant human epidermal growth factor(1-48) in neonates with severe necrotizing enterocolitis. J Pediatr Surg 2007;42:462-9.
55. Feng J, El-Assal ON, Besner GE. Heparin-binding epidermal growth factor-like growth factor reduces intestinal apoptosis in neonatal rats with necrotizing enterocolitis. J Pediatr Surg 2006;41:742-7; discussion 742-7.
56. Feng J, El-Assal ON, Besner GE. Heparin-binding epidermal growth factor-like growth factor reduces intestinal apoptosis in neonatal rats with necrotizing enterocolitis. J Pediatr Surg 2006;41:742-7; discussion 742-7.
57. Yu X, Radulescu A, Zorko N, Besner GE. Heparin-binding EGF-like growth factor increases intestinal microvascular blood flow in necrotizing enterocolitis. Gastroenterology 2009;137:221-30.
58. Chen CL, Yu X, James IO, et al. Heparin-binding EGF-like growth factor protects intestinal stem cells from injury in a rat model of necrotizing enterocolitis. Lab Invest 2012;92:331-44.
59. Radulescu A, Zhang HY, Yu X, et al. Heparin-binding epidermal growth factor-like growth factor overexpression in transgenic mice increases resistance to necrotizing enterocolitis. J Pediatr Surg 2010;45:1933-9.
60. Radulescu A, Yu X, Orvets ND, Chen Y, Zhang HY, Besner GE. Deletion of the heparin-binding epidermal growth factor-like growth factor gene increases susceptibility to necrotizing enterocolitis. J Pediatr Surg 2010;45:729-34.
61. Zhang C, Sherman MP, Prince LS, et al. Paneth cell ablation in the presence of Klebsiella pneumoniae induces necrotizing enterocolitis (NEC)-like injury in the small intestine of immature mice. Dis Model Mech 2012;5:522-32.
62. Goodlad RA, Lee CY, Wright NA. Cell proliferation in the small intestine and colon of intravenously fed rats: effects of urogastrone-epidermal growth factor. Cell Prolif 1992;25:393-404.
63. McAndrew HF, Lloyd DA, Rintala R, van Saene HK. The effects of intravenous epidermal growth factor on bacterial translocation and central venous catheter infection in the rat total parenteral nutrition model. Pediatr Surg Int 2000;16:169-73.
64. Wang JY, Zhang LH, Song WL. Epidermal growth factor regulates intestinal glutamine uptake during total parenteral nutrition. Clin Nutr 1996;15:21-3.
65. Kitchen PA, Goodlad RA, FitzGerald AJ, et al. Intestinal growth in parenterally-fed rats induced by the combined effects of glucagon-like peptide 2 and epidermal growth factor. JPEN J Parenter Enteral Nutr 2005;29:248-54.
66. Pierro A, van Saene HK, Donnell SC, et al. Microbial translocation in neonates and infants receiving long-term parenteral nutrition. Arch Surg 1996;131:176-9.
67. Eizaguirre I, Aldazabal P, Barrena MJ, et al. Effect of growth hormone, epidermal growth factor, and insulin on bacterial translocation in experimental short bowel syndrome. J Pediatr Surg 2000;35:692-5.
68. Stern LE, Erwin CR, O'Brien DP, Huang F, Warner BW. Epidermal growth factor is critical for intestinal adaptation following small bowel resection. Microsc Res Tech 2000;51:138-48.
69. Feng Y, McDunn JE, Teitelbaum DH. Decreased phospho-Akt signaling in a mouse model of total parenteral nutrition: a potential mechanism for the development of intestinal mucosal atrophy. Am J Physiol Gastrointest Liver Physiol 2010;298:G833-41.
70. Nose K, Yang H, Sun X, et al. Glutamine prevents total parenteral nutrition-associated changes to intraepithelial lymphocyte phenotype and function: a potential mechanism for the preservation of epithelial barrier function. J Interferon Cytokine Res 2010;30:67-80.
71. Chiu T, Santiskulvong C, Rozengurt E. EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway. Am J Physiol Gastrointest Liver Physiol 2005;288:G182-94.
72. Laukoetter MG, Mennigen R, Hannig CM, et al. Intestinal cancer risk in Crohn's disease: a meta-analysis. J Gastrointest Surg 2011;15: 576-83.
73. Higashi D, Futami K, Ishibashi Y, et al. Clinical course of colorectal cancer in patients with ulcerative colitis. Anticancer Res 2011;31:2499-504.
74. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68.
75. Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010;316:1083-100.
76. Maurer CA, Friess H, Kretschmann B, et al. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 1998;29:771-7.
77. Leung SP, Griffith OL, Masoudi H, et al. Clinical utility of type 1 growth factor receptor expression in colon cancer. Am J Surg 2008;195: 604-10.
78. Sundvall M, Korhonen A, Paatero I, et al. Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci USA 2008;105:4162-7.
79. Shtiegman K, Kochupurakkal BS, Zwang Y, et al. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene 2007;26:6968-78.
80. Yoda K, Miyazawa K, Hosoda M, Hiramatsu M, Yan F, He F. Lactobacillus GG-fermented milk prevents DSS-induced colitis and regulates intestinal epithelial homeostasis through activation of epidermal growth factor receptor. Eur J Nutr 2013; e-pub ahead of print 7 March 2013.